Form 4 for NVCR NovoCure Ltd
Accepted 2023-11-03 00:00:00 ET · period of report 2023-10-31 · accession 0001562180-23-007549 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-03 | 2023-10-31 | NVCR | Puri Michal Nath | CHRO | A - Grant | $0.00 | +37.6K | 37.6K | New | $0 |
| D | 2023-11-03 | 2023-10-31 | NVCR | Puri Michal Nath | CHRO | A - Grant | $13.30 | +57.6K | 57.6K | New | +$766.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-10-31 | A | A | 37,593 | $0.00 | 37,593 | D | — | — | (F1) Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-10-31 | A | A | 57,604 | $13.30 | 57,604 | D | $13.30 · 2024-10-31 to 2033-10-30 | 57,604 Ordinary Shares | (F2) These stock options will vest in equal parts on the first, second, third and fourth anniversary of the grant date. |